McCarthy, M; (2020) Brussels' global health research agenda: is the balance right? In: Proceedings of Health systems, health economies and globalisation: social science perspectives. : London School of Economics..

Preview

Text McCarthy - European research and globalization.pdf - Accepted Version Download (184kB) | Preview

Abstract

In late 2009, the European Commission held an open consultation on global health asking 26 questions including 3 specifically on health research. In March 2010 the Commission published a Communication on Global Health, and in June three Commission directorates – Health, Development and Research – is holding an international Conference with participants from governments, international organisations and “the private sector – academia, academia, industry, civil society, professional groups and other NGOs” [sic]. Europe is giving increasing emphasis to research, including a rising proportion of the EU's budget. The so-called 'Lisbon Agenda' seeks to make Europe 'the leading knowledge-based economy in the world'. But research to benefit the economy is increasingly seen in terms of 'innovation' to 'make industry more competitive', while the economic and social benefits of not-for-profit innovation are not represented. These issues are also now being played out in the EU Global Health agenda. Of six themes in the June Conference, two are related to research. But the first of the two, 'Innovation and Access', concerns drug development and distribution, while the second, 'Research: local and global challenges', concerns structures, capacity-building and health systems research. Two components are missing in the formulation of global health research: public interest – not just patients and providers – voices in research agendas; and sufficient support for (especially social) research on public-health interventions, both for communicable and non-communicable diseases. Because thCe critical incentive, money, indirectly or directly comes from public budgets, governments should respond as much to civil society interests as to industry lobbies, and should seek benefits of 'innovation' within health systems as well as benefiting the for-profit sector. Health research markets deserve careful attention. Research studies are now addressing these themes in Europe, and are needed globally. Notes para on civil societies and what they can contribute get the latest FP7 strategy Deconstruct 'innovation' Indicate the relevance of market structuring for promoting innovation and therefore productive efficiency. Take the example of prevention – always value for money – versus pharma

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item